EQS-News: ACM Biosciences closes first financing round to accelerate the development of its polymersome vaccine platform and a second-generation COVID-19 vaccine

The proprietary Artificial Cell Membranes (ACMs) are based on an innovative nanotechnology platform using non-immunogenic polymersomes as its carrier.